The objective was to evaluate the effectiveness and safety, with a specific focus on cardiovascular safety, of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, compared to insulin glargine in adults with type 2 diabetes and a high risk of cardiovascular events who have not achieved adequate control with oral glucose-lowering medications.This phase 3 study was conducted at 187 sites across 14 countries on five continents
Side effects Most common: nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, decreased appetite, fatigue, and injection-site reactions
Semaglutide, dulaglutide, and liraglutide are established alternatives, though they too can cause gastrointestinal side effects
If you realize the error before injecting, simply push the plunger back, discard the solution safely, and redraw the correct amount
The guide to taking multiple peptides and the peptide stack calculator help evaluate potential combinations